uplizna
Uplizna (Inebilizumab-Cdon) is a medication used to treat Neuromyelitis Optica.
Inebilizumab-Cdon · by Viela Bio
Key facts
- Active ingredient
- Inebilizumab-Cdon
- Form
- Injectable
- Strength
- INEBILIZUMAB-CDON 100MG/10ML
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- neuromyelitis optica
- Manufacturer
- Viela Bio
- FDA application
- BLA761142
May treat (source: NIH RxClass)
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Uplizna treat?
- Uplizna (Inebilizumab-Cdon) may be used to treat neuromyelitis optica, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Uplizna?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Uplizna. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Uplizna?
- Uplizna is marketed by Viela Bio. You can see Viela Bio's full profile, rating, and other products on pharmaranks.
- Is Uplizna a brand-name or generic drug?
- Uplizna is a brand-name product with the active ingredient Inebilizumab-Cdon.
- Is Uplizna available over the counter?
- No. Uplizna is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Uplizna come in?
- Uplizna is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Uplizna FDA-registered?
- Uplizna is on record with the U.S. FDA under application number BLA761142. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about INEBILIZUMAB-CDON
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2 reports naming INEBILIZUMAB-CDON — the active ingredient in Uplizna, and the FDA flagged 50% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hypersensitivity1 reports
- neuromyelitis optica spectrum disorder1 reports
Read these as a signal, not a rate. A report does not mean INEBILIZUMAB-CDON caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Uplizna head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
uplizna
New